![](/img/cover-not-exists.png)
Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells
Benjamin Bonavida, Toshiharu Tsuchitani, Jacob Zighelboim, Jonathan S. BerekVolume:
38
Year:
1990
Language:
english
DOI:
10.1016/0090-8258(90)90068-v
File:
PDF, 624 KB
english, 1990